From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dirlotapide structure.svg
Dirlotapide ball-and-stick model.png
Clinical data
Trade names Slentrol
AHFS/Drugs.com International Drug Names
Routes of
ATCvet code
Legal status
Legal status
Pharmacokinetic data
Protein binding High[1]
Metabolism Hepatic
Biological half-life 5–18 hours (increased with repeated dosing)
Excretion Feces, urine
CAS Number
PubChem CID
Chemical and physical data
Formula C40H33F3N4O3
Molar mass 674.71 g/mol
3D model (JSmol)

Dirlotapide is a drug used to treat obesity in dogs.[1] It is manufactured by Pfizer and Zoetis and marketed under the brand name Slentrol.

It works as a gut-selective microsomal triglyceride transfer protein (MTTP or MTP) inhibitor.[2] This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.


It is supplied as an oral solution. It is not intended for use in humans, cats, birds, rodents, or other animals.

Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It is used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma.

Regulation and safety[edit]

On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs.[3][4]

However, concerns have since been raised, since 2010, about adverse effects[5] that might more strongly affect particular breeds.[6]

Dirlotapide (under the brand name Slentrol) was authorized for use in the EU by the European Medicines Agency for helping weight loss in dogs, but has since been withdrawn from the market in the EU.[7]